Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | LAP3 | P28838 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265176 | 1.00 | ALDH1A1 (0.58) | ALDH1A1CTSBMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL12764099 | 1.00 | ALDH1A1 (0.58) | ALDH1A1CTSBMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL8268036 | 0.93 | LMNA (0.54) | ALDH1A1CTSBMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL16080197 | 0.93 | LMNA (0.54) | ALDH1A1CTSBMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL13534745 | 0.92 | ALDH1A1 (0.50) | ALDH1A1CTSBMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL14599839 | 0.92 | ALDH1A1 (0.50) | ALDH1A1CTSBMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL38661393 | 0.91 | ALDH1A1 (0.49) | ALDH1A1CTSBMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL22064243 | 0.91 | ALDH1A1 (0.49) | ALDH1A1CTSBMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL22930081 | 0.91 | ALDH1A1 (0.59) | ALDH1A1CTSBL3MBTL1KMT2ATDP1 | |
| SCHEMBL25901508 | 0.89 | LTA4H (0.65) | L3MBTL1LTA4HLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871916-B2 | Diaryl phosphine compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871916-B2 | Diaryl phosphine compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20130203974-A1 | Preparation of Diazo and Diazonium Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-08 | — | — | US | disclosed |
| US-8324174-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120277146-A1 | Compounds For Enzyme Inhibition | ONYX PHARMACEUTICALS INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8207126-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207127-B2 | Compounds for enzyme inhibition | ONYX TECHNOLOGIES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207125-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120094929-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094930-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094928-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094926-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090275727-A1 | Peptide turn mimetics | MIMETICA PTY LIMITED (AU) | 2009-11-05 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275727-A1 | Peptide turn mimetics | IAPP, GLP1R, VIP | ALDH1A1 4876/4885CTSB 1186/4885MAPK1 4047/4885 |
| US-20120094929-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | ALDH1A1 2975/4885CTSB 32/4885MAPK1 2326/4885 |
| US-20130203974-A1 | Preparation of Diazo and Diazonium Compounds | TREH, TALDO1, LIPE | ALDH1A1 2593/4885CTSB 3007/4885MAPK1 428/4885 |
| US-20120094928-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | ALDH1A1 2975/4885CTSB 32/4885MAPK1 2326/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | ALDH1A1 2376/4885CTSB 4155/4885MAPK1 2117/4885 |
| US-20120094926-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | ALDH1A1 2975/4885CTSB 32/4885MAPK1 2326/4885 |
| US-20120094930-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | ALDH1A1 2975/4885CTSB 32/4885MAPK1 2326/4885 |
| US-20120277146-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | ALDH1A1 2975/4885CTSB 32/4885MAPK1 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.